Loyola Enrolling Patients in Clinical Trial Using PET Scans to Diagnose Alzheimer’s

Loyola Enrolling Patients in Clinical Trial Using PET Scans to Diagnose Alzheimer’s
Loyola Medicine will participate in a landmark $100 million study called “Imaging Dementia – Evidence for Amyloid Scanning (IDEAS)” to evaluate the effectiveness of using positron emission tomography (PET) scans to detect Alzheimer’s disease (AD). The IDEAS (NCT02420756) study is based on the rationale that because clumps of amyloid proteins, which block signals in the brain, have been observed in AD patients and PET scans can detect these amyloid plaques, PET scans potentially could be used in new ways to diagnose AD. The American College of Radiology Imaging Network and the Alzheimer’s Association are sponsoring the study. Leading the Loyola team are principal investigators Moises Gaviria, MD, a neuropsychiatrist, and Robert Wagner, MD, medical director of nuclear medicine. PET scans could decrease the uncertainty of an AD diagnosis and increase confidence in the underlying cause of a patient’s cognitive impairment, leading to earlier counseling and intervention and potentially resulting in improved outcomes. A PET scan uses a tracer drug injecte
Subscribe or to access all post and page content.

2 comments

    • Tim Bossie says:

      Hi Linda, you will have to talk with your doctor about the possibility of taking place in this study and if it is available in your area.

Leave a Comment

Your email address will not be published. Required fields are marked *